FDA NDA · NDA216059

JAYPIRCA

Sponsor: LOXO ONCOL

What this page does not claim

A drug page is a reference view of public FDA data (Drugs@FDA), reproduced as published. SPEQ is not affiliated with the FDA, adds no interpretation to the record, and nothing here is medical, legal, or regulatory advice.

APPLICATION
NDA216059
TYPE
NDA
ORIGINAL APPROVAL
2023-01-27
LATEST ACTION
2026-10-02
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

JAYPIRCA · ReferencePrescription
PIRTOBRUTINIB 50MG · TABLET · ORAL
JAYPIRCA · ReferencePrescription
PIRTOBRUTINIB 100MG · TABLET · ORAL

Approval history

2026-10-02Efficacy · Supplement 6 · standard — Label ↗AP
2025-12-02Efficacy · Supplement 5 · standard — Label ↗AP
2024-06-04Labeling · Supplement 2 · 901 required — Letter ↗AP
2023-12-01Efficacy · Supplement 1 · priority — Label ↗AP
2023-01-27Type 1 - New Molecular Entity · Original · priority — Label ↗AP